

**NOTICE OF CHANGE IN CORPORATE STRUCTURE  
PURSUANT TO  
SECTION 4.9 OF NATIONAL INSTRUMENT 51-102**

**Item 1: Name of the Parties to the Transaction**

Love Pharma Inc. (the “**Corporation**”) (formerly Glenbriar Technologies Inc. (“**GTI**”))  
Kick Pharmaceuticals Inc. (“**Kick**”)  
1270412 Ltd. (“**Subco**”)  
1288339 B.C. Ltd.

**Item 2: Description of the Transaction**

The Corporation has requalified on the Canadian Securities Exchange (the “**CSE**”) from a technology issuer to a life sciences issuer following completion of a transaction, which constitutes a “Fundamental Change” (as such term is defined in Policy 8 of the CSE Policies) (the “**Transaction**”). The Transaction was effected by the completion of the acquisition of 100% of the issued and outstanding common shares of Kick by the Corporation concurrently with the acquisition of 100% of the issued and outstanding shares of 1288339 B.C. Ltd., pursuant to which the Corporation redirected its resources and changed the nature of its business from that of a technology issuer to a life sciences issuer.

In connection with the Transaction, the Corporation changed its name to Love Pharma Inc. and effected a two-for-one consolidation. The Corporation issued 183,067,857 shares, at a deemed value of \$0.10 per share, to the shareholders of Kick and 20,000,000 shares to the shareholders of 1288339 B.C. Ltd. at a deemed price of \$0.10 and issued 3,000,000 shares at a deemed price of \$0.10 to Callitas Health, Inc., pursuant to certain product license agreements. Post Transaction and these other transactions, there are 314,919,945 shares issued and outstanding with an additional 73,626,130 shares reserved for issuance, pursuant to various warrants. Of the shares currently issued and outstanding, 140,500,000 shares are subject to trading restrictions until January 23, 2022. An additional 3,494,000 shares are subject to a three-year escrow agreement, in accordance with CSE Policies.

This Transaction is treated for accounting purposes as a reverse take over of Kick, whose year end is December 31.

**Item 3: Effective Date of Transaction**

September 30, 2021

**Item 4: Names of Each Party, if any that Ceased to be a Reporting Issuer after the Transaction and of Each Continuing Party**

The Corporation continues to be a reporting issuer in Alberta and British Columbia.

**Item 5: Date of Reporting Issuer's First Financial Year-End Subsequent to the Transaction (if paragraph (a) or subparagraph (b)(ii) of s. 4.9 applies)**

The Corporation's first financial year-end subsequent to the Transaction will end on December 31, 2022.

**Item 6: Periods, Including Comparative Periods, if any, of the Interim and Annual Financial Statements Required to be Filed for the Reporting Issuer's First Financial Year After the Transaction (if paragraph (a) or subparagraph (b)(ii) of s. 4.9 applies)**

- a) Annual financial statements for the year ended December 31, 2021;
- b) Interim financial statements for the 3, 6 and 9 month periods ended March 31, June 30 and September 30, 2021 and 2020; and

**Item 7: Documents Filed Under NI 51-102 that Described the Transaction and Where Those Documents Can be Found in Electronic Format (if paragraph (a) or subparagraph (b)(ii) of s. 4.9 applies)**

- a) Press release of GTI dated November 4, 2020;
- b) Material change report of GTI dated November 4, 2020;
- c) Management Information Circular of GTI containing information as at January 28, 2021;
- d) Filing Statement dated September 22, 2021;
- e) Press release of the Corporation dated September 30, 2021 announcing the closing of the Transaction, that it has changed its name and effected a share consolidation;
- f) Merger Agreement among GTI, Kick and Subco dated October 30, 2020;
- g) First amending agreement dated as of November 30, 2020 among GTI, Kick and Subco;
- h) Second amending agreement dated as of July 15, 2020 among GTI, Kick and Subco; and
- i) Interim financial statements for the 3 and 6 months ended June 30, 2021 and 2020.

**Dated:** December 8, 2021